1.
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
by Schöffski, Patrick, Prof
The Lancet (British edition), 2016, Vol.387 (10028), p.1629-1637
2.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
by Gnant, Michael, Prof
The lancet oncology, 2011, Vol.12 (7), p.631-641
3.
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
by Barlesi, Fabrice
The lancet oncology, 2018-11, Vol.19 (11), p.1468-1479
4.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall surviv...
by Ryan, Charles J, Prof
The lancet oncology, 2015, Vol.16 (2), p.152-160
5.
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
by Esser, Nathalie
Diabetologia, 2019-05-14, Vol.62 (7), p.1113-1122
6.
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
by Helleday, Thomas
Nature, 2005-04-14, Vol.434 (7035), p.913-917
7.
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON...
by The International Collaborative Ovarian Neoplasm (ICON) Group
The Lancet (British edition), 2002, Vol.360 (9332), p.505-515
8.
Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells
by Eid, Safaa Yehia
Phytomedicine (Stuttgart), 2012-11-15, Vol.19 (14), p.1288-1297
9.
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model
by Bernardi, Andressa
Cancer letters, 2009, Vol.281 (1), p.53-63
10.
Neoadjuvant Therapy for Breast Cancer
by Zardavas, Dimitrios
Annual review of medicine, 2015-01-14, Vol.66 (1), p.31-48
11.
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
by Wildiers, Hans, Dr, Prof
The lancet oncology, 2007, Vol.8 (12), p.1101-1115
12.
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients
by Cai, Zhen
Phytomedicine (Stuttgart), 2016-11-15, Vol.23 (12), p.1295-1300
13.
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
by Masi, Gianluca
Nature reviews. Clinical oncology, 2009-11, Vol.6 (11), p.670-674
14.
Treatment of Congenital Hyperinsulinism with Lanreotide Acetate (Somatuline Autogel)
by Modan-Moses, Dalit
The journal of clinical endocrinology and metabolism, 2011-08, Vol.96 (8), p.2312-2317
15.
Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting
by Tang, Grace H
Medical oncology (Northwood, London, England), 2017-08-04, Vol.34 (9), p.154
16.
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity
by Benson, John R
Future oncology (London, England), 2020-05-01, Vol.16 (21), p.1503-1509
17.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
by Bruix, Jordi, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.56-66
18.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof
The lancet oncology, 2015, Vol.16 (8), p.908-918
19.
Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations
by Goonewardene, Tyronne I, MRCP
The lancet oncology, 2007, Vol.8 (9), p.813-821
20.
